PathAI Publications
Efruxifermin drives multidimensional histologic improvement in compensated cirrhosis: an AI-based analysis from the SYMMETRY randomized controlled trial
Written by
Admin
| Nov 5, 2026, 2:00:00 PM
Conference
AASLD
Partner
Akero Therapeutics
View Presentation
View full post